# Bardy Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bardy-diagnostics

- Industry: Medical Devices & Equipment
- Headquarters: Seattle, US
- Website: www.bardydx.com
- Total disclosed funding: $36M
- Latest round: Series B (Apr 11, 2019)
- Investors on record: 9

## About

Bardy Diagnostics is a Seattle-based company specializing in innovative cardiac monitoring solutions, focusing on providing advanced technologies for diagnosing atrial arrhythmias.Founded in 2013 in Seattle, US, Bardy Diagnostics develops specialized cardiac monitoring devices. The company has undergone a strategic shift leading to its acquisition by Hill-Rom Services Inc. in January 2021 for USD 375 mn. The CEO is Kevin Hykes, and the founder Gust Bardy has a background in pioneering healthcare technology.Bardy Diagnostics specializes in advanced cardiac monitoring solutions, particularly with its flagship product, the Carnation Ambulatory Monitor (CAM). Launched in 2013, the CAM is a lightweight ECG patch monitor designed for high-quality atrial signal capture, facilitating accurate arrhythmia diagnoses. The company serves hospitals and cardiology clinics in the United States, aiming to improve diagnostic processes and patient outcomes.Bardy Diagnostics generates revenue primarily through the sales of its CAM and associated services, including the BDxCONNECT patient management portal. The company uses a business-to-business model, engaging healthcare providers in subscription agreements for monitoring devices and comprehensive reporting services. The CAM Report is delivered within 48 hours of data upload, ensuring swift access to critical patient information.The recent acquisition by Hill-Rom Services Inc. will enable Bardy Diagnostics to further develop its cardiac monitoring solutions and expand into new markets. The funding from the USD 375 mn deal will support the launch of next-generation products and enhance service capabilities. The company is focused on increasing its market presence in North America and exploring opportunities in international markets through 2023.

## Funding rounds

- Series B, Apr 11, 2019, $36M — RC Capital, SV Health Investors, Aperture Venture Partners, Aphelion Capital, Ascension Ventures, Health Enterprise Partners, HealthQuest Capital, Rex Health Ventures, Lumira Ventures

## Investors

- RC Capital (https://capitalatlas.ai/funds/rc-capital) — Series B
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series B
- Aphelion Capital (https://capitalatlas.ai/funds/aphelion-capital) — Series B
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series B
- Health Enterprise Partners (https://capitalatlas.ai/funds/health-enterprise-partners) — Series B
- HealthQuest Capital (https://capitalatlas.ai/funds/healthquest-capital) — Series B
- Rex Health Ventures (https://capitalatlas.ai/funds/rex-health-ventures) — Series B
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series B